On the other hand, there is ample support for a role of CD28 co-stimulation in the pathogenesis of GCA (63), and treatment with CTLA4-Ig, which blocks CD28, has been shown to reduce the risk of relapse in patients with GCA (115). Here, CD28 is linked to temporal arteritis.